The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Just eight seconds into the start of the 2025 award show season, Nikki Glaser, the host of the 82nd Golden Globes, dubbed the ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 492.13% and ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...